Skip to main content

Day: March 21, 2024

Else Nutrition Schedules 2023 Fiscal Year Business Update Conference Call

VANCOUVER, British Columbia, March 21, 2024 (GLOBE NEWSWIRE) — ELSE NUTRITION HOLDINGS INC. (BABY) (BABYF) (0YL.F) (“Else” or the “Company”), today announced that it plans to host a business update conference call at 10:30 a.m. Eastern Time on April 1, 2024 to discuss the Company’s financial results for the 2023 fiscal year ended December 31, 2023, as well as the Company’s corporate progress and other developments. The conference call will be available via telephone by dialing toll free 1-877-704-4453 for U.S. callers or +1-201-389-0920 for international callers. A webcast of the call may be accessed at https://viavid.webcasts.com/starthere.jsp?ei=1661271&tp_key=87e7860827 or on the Investor Relations section of the Company’s website at https://investors.elsenutrition.com/. A webcast replay will be...

Continue reading

TEN, Ltd. Announces Date of Fourth Quarter and Year End 2023 Results, Conference Call and Webcast

ATHENS, Greece, March 21, 2024 (GLOBE NEWSWIRE) — TEN, Ltd. (“TEN” or the “Company”) (NYSE: TNP) a leading diversified crude, product and LNG tanker operator, today announced that the Company will report earnings for the fourth quarter and year ended on December 31, 2023, prior to the open of the market in New York on Wednesday, March 27, 2024. That same day, at 12:00 p.m. Eastern Time, TEN will host a conference call to review the results as well as the management’s outlook for the business. The call, which will be hosted by TEN’s senior management, may contain information beyond that which is included in the earnings press release. Conference Call Details:Participants should dial into the call 10 minutes before the scheduled time using the following numbers: 877-405-1226 (US Toll-Free Dial In) or +1 201-689-7823 (US and...

Continue reading

Awiqli® (once-weekly basal insulin icodec) recommended for approval for the treatment of diabetes by the European regulatory authorities

Bagsværd, Denmark, 21 March 2024 – Novo Nordisk today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending marketing authorisation for Awiqli® (the brand name for once-weekly basal insulin icodec) for treatment of diabetes in adults. The positive CHMP opinion is based on results from the ONWARDS phase 3a clinical trial programme. Once-weekly basal insulin icodec achieved superior blood sugar reduction1 (measured by a change in HbA1c) and superior Time in Range2 (time spent within recommended blood sugar range), compared with daily basal insulin in people with type 2 diabetes. In people with type 2 diabetes who have not previously been treated with insulin, overall observed rates of clinically significant or severe hypoglycaemia3 were below one...

Continue reading

Dogfish Head Craft Brewery to Launch Sippin’ & Flippin’ Giveaway, Winner to Receive All-Expenses Paid Trip to a Concert of Their Choice

Sippin’ & Flippin’ to kick-off Dogfish Head’s month-long music celebration, which includes a partnership with Record Store Day, a host of sponsored concerts and events, and more.Dogfish Head’s Sippin’ & Flippin’ Concert GiveawayThroughout the month of April, in select independently owned record stores from coast-to-coast, Dogfish Head will hide commemorative, metallic-gold records among the shops’ stacks of vinyl. Lucky folks that stumble upon a golden record will not only win a swag bag full of goodies, but they will be entered for the chance to win the contest’s grand-prize trip – an all-expenses paid trip for two to a concert of their choosing.MILTON, Del., March 21, 2024 (GLOBE NEWSWIRE) — Self-proclaimed “beer geeks with a music problem,” Dogfish Head Craft Brewery announces Sippin’...

Continue reading

SPZI: JP 3E Holdings, Inc. Retains Accell Audit & Compliance, PA to Audit the Financial Statements

JP 3E Holdings, Inc., formerly Spooz Inc., will become a Fully Reporting Company, Retaining Accell Audit & Compliance, PA in pursuit of Uplisting CLEARWATER, Fla., March 21, 2024 (GLOBE NEWSWIRE) — JP 3E Holdings, Inc., formerly Spooz, Inc. (OTC: SPZI), retains Accell Audit & Compliance, PA to audit the company’s financials to become an SEC Fully Reporting company. This is the first step toward achieving its goal of uplisting first to the OTCQB. Accell is registered with the Public Company Accounting Oversight Board (PCAOB) and provides audit services to several hundred clients, from high-tech start-up companies to Fortune 500. Its current client portfolio includes numerous public and private companies across many industries, with operations on at least five continents.http://www.theaccellgroup.com/ Accell is a licensed...

Continue reading

Savaria Declares Monthly Dividend (Record Date Correction)

LAVAL, Quebec, March 21, 2024 (GLOBE NEWSWIRE) — Savaria Corporation (“Savaria”) (TSX: SIS) a global leader in the accessibility industry, declared today a dividend of 4.33 cents ($0.0433) per common share, in accordance with its monthly dividend policy, payable on April 10, 2024, to shareholders of record of the Corporation at the close of business on March 28, 2024. This is an eligible dividend within the meaning of the Income Tax Act. About Savaria Corporation Savaria Corporation (savaria.com) is a global leader in the accessibility industry. It provides accessibility solutions for the physically challenged to increase their comfort, their mobility and their independence. Its product line is one of the most comprehensive on the market. Savaria designs, manufactures, distributes and installs accessibility equipment, such as stairlifts...

Continue reading

Scilex Holding Company Announces New Out-of-Pocket Costs for Commercially Insured Patients

PALO ALTO, Calif., March 21, 2024 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that the out-of-pocket costs for its product portfolio for commercially insured patients is expected to be capped at $25 monthly, with certain eligible patients paying as low as $0. This applies to the Company’s postherpetic neuralgia pain product, ZTlido®, migraine product, ELYXYB®, and gout flare prophylaxis product, Gloperba®, which is expected to launch in the first half of 2024. Scilex has made significant investments to improve patient affordability and access to its products and continues to build on the Company’s...

Continue reading

No. 6/2024 – Course of the annual general meeting

Nasdaq Copenhagen                                                                                    Nikolaj Plads 6 DK-1067 Copenhagen K    Copenhagen, 21 March 2024 ANNOUNCEMENT no. 6/2024 CEMAT A/SCompany reg. (CVR) no. 24 93 28 18Annual general meeting 2024 On 21 March 2024 at 1:00 pm the annual general meeting was held in Cemat A/S (the “Company”) at DLA Piper Denmark, Oslo Plads 2, 2100 Copenhagen Ø. Pursuant to the Company’s articles of association, the Board of Directors had appointed attorney-at-law Martin Lavesen as chairman of the meeting.The management’s report on the Company’s activities during the past financial yearThe management’s report for the financial year 2023 was presented by management. The annual general meeting took note of the management’s report for the financial year 2023.Presentation of the audited...

Continue reading

Red Pine Exploration Announces the Results of its Annual General Meeting, Provides Update & Grants Annual Stock Option Awards

TORONTO, March 21, 2024 (GLOBE NEWSWIRE) — Red Pine Exploration Inc. (TSXV: RPX, OTCQB; RDEXF) (“Red Pine” or the “Company”) is pleased to announce the results of its Annual General Meeting of Shareholders (the “Meeting”) held virtually on March 12, 2024. At the Meeting, the shareholders:elected Drew Anwyll, Gary O’Connor, Rachel Goldman, Paul Martin and Quentin Yarie as directors of the Company; and reappointed MNP LLP, Chartered Professional Accountants as the Company’s auditors until the next annual meeting of shareholders, and to authorize the directors to set their renumeration.Mr. Paul Martin commented, “We are extremely fortunate to have added Gary O’Connor to the Board given his extensive experience in the evaluation and development of resources, including most recently at the Tower Gold project located in the Timmins...

Continue reading

US Capital Global Achieves Record-breaking Average of $2.2BN in Financing and Advisory Transactions Per Year over the Past Three Years

Closing 90 transactions totalling over $6.5 billion in 36 months, US Capital Global demonstrates substantial growth, further solidifying its position as a leading player in the global financial arena.Closing 90 transactions totalling over $6.5 billion in 36 monthsThat’s a record-breaking average of $2.2BN in Financing and Advisory transactions per year over the past three yearsSelection of Completed Transactionshe breadth and scale of transactions we facilitated underscore the strength of our global footprintSan Francisco, California, USA, March 21, 2024 (GLOBE NEWSWIRE) — US Capital Global proudly announces a landmark achievement, surpassing an average of $2.2 billion in debt and equity financings and advisory transactions per year over the past three years. Headquartered in San Francisco, with key offices...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.